Potential Biomarkers of Long-term Benefit from Single-agent Trastuzumab or Lapatinib in HER2-positive Metastatic Breast Cancer

ABSTRACT: Gene expression data of HER2+ breast tumor samples Increasing evidence indicates that a subset of patients with HER2-positive breast cancer may achieve significant clinical benefit with anti-HER2 targeted therapy without chemotherapy. Thus, identification of biomarkers of long-term benefit from anti-HER2 agents is needed, especially in the metastatic setting. In the HERLAP study (NCT00842998), patients with HER2-positive metastatic breast cancer were randomized to trastuzumab or lapatinib as first-line therapy. Patients showing radiological signs of tumor regression after 8 weeks of treatment were allowed to continue on single agent anti-HER2 therapy until disease progression. Chemotherapy was added to anti-HER-2 therapy in patients failing to achieve tumor regression at the 8-week evaluat

ORGANISM(S): Homo sapiens

SUBMITTER: Aleix Prat 

PROVIDER: E-GEOD-46350 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress